IASLC Board Member to Chair SWOG Committee
On April 1, 2022, Jhanelle Gray, MD, who is chair of the Department of Thoracic Oncology at Moffitt Cancer Center at the University of Florida, Tampa, began leading SWOG Cancer Research Network’s Lung Cancer Committee. Dr. Gray succeeds IASLC CEO Karen Kelly, MD.
Dr. Gray leads numerous clinical research trials that investigate novel immunotherapeutic and targeted therapy drug combinations for lung cancer. She is an active member and leader of many cancer organizations, including the IASLC, where she serves on the board of directors and the Women in Thoracic Oncology Working Group.
Distinguished Professor and Active IASLC Leader Masayuki Noguchi Retires
Upon his recent retirement, ILCN gratefully acknowledges the vast, far-reaching contributions of Masayuki Noguchi, MD, PhD, professor of diagnostic pathology, University of Tsukuba, Japan.
A longtime IASLC member, Dr. Noguchi is a worldwide leader in the field of surgical and molecular pathology of lung carcinoma. For more than 20 years, he has dedicated countless hours to advancements in the field and to support the mission of the IASLC to conquer thoracic malignancy worldwide.
As former chair of the IASLC Pathology Committee, he was a strong advocate for harmonization of molecular testing. In that role, he helped promote and strengthen the association worldwide, creating connections among members and societies for global collaboration. In 2009, Dr. Noguchi received an IASLC Distinguished Service Award in recognition of his accomplishments.
He has continued to contribute to the organization and profession since. In more recent years, he served on the IASLC Board of Directors and as president of the World Conference on Lung Cancer during years of record membership and conference attendance.
On behalf of the IASLC board, staff, and members, we express our profound gratitude to Dr. Noguchi for a lifetime of service and for his dedication to IASLC.
Dr. Triparna Sen Joins Mount Sinai
In March 2022, Triparna Sen, PhD, joined the Icahn School of Medicine at Mount Sinai, New York, as a tenure track associate professor and co-director of the Lung Cancer Preclinical Model Development platform. The Sen Lab is focused on the development of new treatment paradigms for molecular subsets of lung cancer. Previously, Dr. Sen was at Memorial Sloan Kettering Cancer Center, New York.
Have news to share? Email [email protected].